Transoral vertebroplasty for the C1 lateral mass.


Journal

Journal of neurointerventional surgery
ISSN: 1759-8486
Titre abrégé: J Neurointerv Surg
Pays: England
ID NLM: 101517079

Informations de publication

Date de publication:
Sep 2020
Historique:
received: 01 02 2020
revised: 01 04 2020
accepted: 04 04 2020
pubmed: 2 5 2020
medline: 2 12 2020
entrez: 2 5 2020
Statut: ppublish

Résumé

Osteolytic lesions of the atlas (C1) are challenging to treat by vertebroplasty due to the vicinity of the vertebral artery and the spinal cord. To present our experience with transoral vertebroplasty (TOV) for osteolytic lesions of the lateral mass of the atlas. Retrospective case series involving 15 consecutive patients (nine male, six female, mean age 63 years) who underwent TOV for the treatment of an osteolytic lesion of the lateral mass of the atlas. Among the osteolytic lesions, 10/15 (67%) were bone metastases from various cancers; 4/15 (27%) were lesions related to multiple myeloma; and one lesion (7%) was an aggressive hemangioma. All the TOVs were performed under general anesthesia and in most cases (10/15; 67%) in a hybrid angiosuite combining a C-arm flat panel and a CT scan. The remaining five patients were treated under biplane fluoroscopic guidance. Vertebroplasty of the lateral mass of C1 through a transoral route was feasible in all cases. Significant pain relief was obtained in most cases (1 month average decrease in Numeric Rating Scale: 4.9±4.1). No major complication was recorded. In 7/15 cases (47%), cement leakage surrounding the C1 lateral mass was seen; none of these leakages had a significant clinical consequence. No additional spine surgery was required in any of the patients. TOV of osteolytic lesions of the lateral mass of the atlas is feasible and seems safe and effective, providing pain relief and bone stabilization.

Sections du résumé

BACKGROUND BACKGROUND
Osteolytic lesions of the atlas (C1) are challenging to treat by vertebroplasty due to the vicinity of the vertebral artery and the spinal cord.
OBJECTIVE OBJECTIVE
To present our experience with transoral vertebroplasty (TOV) for osteolytic lesions of the lateral mass of the atlas.
METHODS METHODS
Retrospective case series involving 15 consecutive patients (nine male, six female, mean age 63 years) who underwent TOV for the treatment of an osteolytic lesion of the lateral mass of the atlas. Among the osteolytic lesions, 10/15 (67%) were bone metastases from various cancers; 4/15 (27%) were lesions related to multiple myeloma; and one lesion (7%) was an aggressive hemangioma. All the TOVs were performed under general anesthesia and in most cases (10/15; 67%) in a hybrid angiosuite combining a C-arm flat panel and a CT scan. The remaining five patients were treated under biplane fluoroscopic guidance.
RESULTS RESULTS
Vertebroplasty of the lateral mass of C1 through a transoral route was feasible in all cases. Significant pain relief was obtained in most cases (1 month average decrease in Numeric Rating Scale: 4.9±4.1). No major complication was recorded. In 7/15 cases (47%), cement leakage surrounding the C1 lateral mass was seen; none of these leakages had a significant clinical consequence. No additional spine surgery was required in any of the patients.
CONCLUSION CONCLUSIONS
TOV of osteolytic lesions of the lateral mass of the atlas is feasible and seems safe and effective, providing pain relief and bone stabilization.

Identifiants

pubmed: 32354844
pii: neurintsurg-2020-015853
doi: 10.1136/neurintsurg-2020-015853
doi:

Substances chimiques

Bone Cements 0

Types de publication

Journal Article Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

879-885

Informations de copyright

© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: FC reports conflict of interest with Medtronic, Guerbet, Balt Extrusion, Penumbra (payment for readings; non-related to the study), Codman Neurovascular and Microvention (core laboratory; non-related to the study).

Auteurs

Frédéric Clarençon (F)

Sorbonne Université, Paris, France fredclare5@gmail.com.
Department of Interventional Neuroradiology, Hopitaux Universitaires Pitie Salpetriere-Charles Foix, Paris, France.

Eimad Shotar (E)

Department of Interventional Neuroradiology, Hopitaux Universitaires Pitie Salpetriere-Charles Foix, Paris, France.

Evelyne Cormier (E)

Department of Interventional Neuroradiology, Hopitaux Universitaires Pitie Salpetriere-Charles Foix, Paris, France.

Kevin Premat (K)

Sorbonne Université, Paris, France.
Department of Interventional Neuroradiology, Hopitaux Universitaires Pitie Salpetriere-Charles Foix, Paris, France.

Mehdi Drir (M)

Department of Neuro-intensive care, Hopitaux Universitaires Pitie Salpetriere-Charles Foix, Paris, France.

Ghizlene Lahlou (G)

Sorbonne Université, Paris, France.
Department of Otorhinolaryngology, Hopitaux Universitaires Pitie Salpetriere-Charles Foix, Paris, France.

Veronique Morel (V)

Department of Hematology, Hopitaux Universitaires Pitie Salpetriere-Charles Foix, Paris, France.

Jean-Philippe Spano (JP)

Sorbonne Université, Paris, France.
Department of Oncology, Hôpitaux Universitaires Pitié Salpêtrière - Charles Foix, Paris, France.

Raphaël Bonaccorsi (R)

Department of Orthopedic Surgery, Hopitaux Universitaires Pitie Salpetriere-Charles Foix, Paris, France.

Federico Di Maria (F)

Department of Neuroradiology, Hospital Foch, Suresnes, France.

Rémi Hervochon (R)

Department of Otorhinolaryngology, Hopitaux Universitaires Pitie Salpetriere-Charles Foix, Paris, France.

Hugues Pascal-Mousselard (H)

Sorbonne Université, Paris, France.
Department of Orthopedic Surgery, Hopitaux Universitaires Pitie Salpetriere-Charles Foix, Paris, France.

Jacques Chiras (J)

Sorbonne Université, Paris, France.
Department of Interventional Neuroradiology, Hopitaux Universitaires Pitie Salpetriere-Charles Foix, Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH